Yes, Leo designed the trial like Prurisol on purpose IMO. Both Phase 2 trials had small patient size that was unlikely to produce statistically significant result. Both trials enrolled the more severe condition patients so Leo had an excuse when they failed. Both trials had numerous delays.
Be very careful when a CEO cherry-picked certain in-vitro data and touted continuously. By now hopefully some realize the human body works very differently than monkey cells in test tubes or how the computer predicts.
Did Leo F-UP again with the no win trial design like Purisol???
News 
Market Data 
Discover 
